Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Ertugliflozin for Heart Failure
Recruiting0 awardsPhase 2
New Haven, Connecticut
This trial will test whether adding ertugliflozin, metolazone or placebo to intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy can improve heart failure signs and symptoms.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.